REFERENCES
1. Priori SG and Blomström-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J . 2015;36:2757-9.
2. Postema PG. About Brugada syndrome and its prevalence.Europace . 2012;14:925-8.
3. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P and Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J . 2001;22:2290-6.
4. Casado-Arroyo R, Berne P, Rao JY, Rodriguez-Mañero M, Levinstein M, Conte G, Sieira J, Namdar M, Ricciardi D, Chierchia GB, de Asmundis C, Pappaert G, La Meir M, Wellens F, Brugada J and Brugada P. Long-Term Trends in Newly Diagnosed Brugada Syndrome: Implications for Risk Stratification. J Am Coll Cardiol . 2016;68:614-623.
5. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G and Brugada R. Present Status of Brugada Syndrome: JACC State-of-the-Art Review.J Am Coll Cardiol . 2018;72:1046-1059.
6. Vutthikraivit W, Rattanawong P, Putthapiban P, Sukhumthammarat W, Vathesatogkit P, Ngarmukos T and Thakkinstian A. Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol Sin . 2018;34:267-277.
7. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ and Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm . 2018;15:e190-e252.
8. Gonzalez Corcia MC, Sieira J, Pappaert G, de Asmundis C, Chierchia GB, La Meir M, Sarkozy A and Brugada P. Implantable Cardioverter-Defibrillators in Children and Adolescents With Brugada Syndrome. J Am Coll Cardiol . 2018;71:148-157.
9. Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofune M, Nagashima K, Kofune T, Nakai T, Kunimoto S, Kasamaki Y and Hirayama A. Prolonged QRS duration in lead V2 and risk of life-threatening ventricular Arrhythmia in patients with Brugada syndrome. Int Heart J . 2011;52:98-102.
10. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, De Nardis R and Colombo M. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.J Am Coll Cardiol . 2012;59:37-45.
11. Babai Bigi MA, Aslani A and Shahrzad S. aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm . 2007;4:1009-12.
12. Calò L, Giustetto C, Martino A, Sciarra L, Cerrato N, Marziali M, Rauzino J, Carlino G, de Ruvo E, Guerra F, Rebecchi M, Lanzillo C, Anselmino M, Castro A, Turreni F, Penco M, Volpe M, Capucci A and Gaita F. A New Electrocardiographic Marker of Sudden Death in Brugada Syndrome: The S-Wave in Lead I. J Am Coll Cardiol . 2016;67:1427-1440.
13. Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, Paul M, Breithardt G, Haverkamp W and Eckardt L. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol.Eur Heart J . 2003;24:1104-12.
14. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H and Wilde A. Brugada syndrome: report of the second consensus conference. Heart Rhythm . 2005;2:429-40.
15. Sarquella-Brugada G, Campuzano O, Arbelo E, Brugada J and Brugada R. Brugada syndrome: clinical and genetic findings. Genet Med . 2016;18:3-12.
16. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL and Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med . 2015;17:405-24.
17. Milman A, Andorin A, Gourraud JB, Sacher F, Mabo P, Kim SH, Maeda S, Takahashi Y, Kamakura T, Aiba T, Conte G, Juang JJM, Leshem E, Rahkovich M, Hochstadt A, Mizusawa Y, Postema PG, Arbelo E, Huang Z, Denjoy I, Giustetto C, Wijeyeratne YD, Napolitano C, Michowitz Y, Brugada R, Casado-Arroyo R, Champagne J, Calo L, Sarquella-Brugada G, Tfelt-Hansen J, Priori SG, Takagi M, Veltmann C, Delise P, Corrado D, Behr ER, Gaita F, Yan GX, Brugada J, Leenhardt A, Wilde AAM, Brugada P, Kusano KF, Hirao K, Nam GB, Probst V and Belhassen B. Age of First Arrhythmic Event in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 Patients. Circ Arrhythm Electrophysiol . 2017;10.
18. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C and Wilde AA. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation . 2010;121:635-43.
19. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, Di Giovanni G, Saitoh Y, Juliá J, Mugnai G, La Meir M, Wellens F, Czapla J, Pappaert G, de Asmundis C and Brugada P. A score model to predict risk of events in patients with Brugada Syndrome.Eur Heart J . 2017;38:1756-1763.
20. Miyamoto K, Yokokawa M, Tanaka K, Nagai T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S and Shimizu W. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome.Am J Cardiol . 2007;99:53-7.
21. Curcio A, Mazzanti A, Bloise R, Monteforte N, Indolfi C, Priori SG and Napolitano C. Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. J Cardiovasc Electrophysiol . 2016;27:937-43.
22. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, Marquie C, Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field ME, Derval N, Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB, Ploux S, Rollin A, Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jaïs P, Pasquié JL, Hocini M, Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P and Haïssaguerre M. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation . 2013;128:1739-47.
23. Tse G, Gong M, Meng L, Wong CW, Georgopoulos S, Bazoukis G, Wong MCS, Letsas KP, Vassiliou VS, Xia Y, Baranchuk AM, Yan GX and Liu T. Meta-analysis of T. J Electrocardiol . 2018;51:396-401.
24. Morita H, Watanabe A, Kawada S, Miyamoto M, Morimoto Y, Nakagawa K, Nishii N, Nakamura K and Ito H. Identification of electrocardiographic risk markers for the initial and recurrent episodes of ventricular fibrillation in patients with Brugada syndrome. J Cardiovasc Electrophysiol . 2018;29:107-114.
25. Sieira J, Conte G, Ciconte G, de Asmundis C, Chierchia GB, Baltogiannis G, Di Giovanni G, Saitoh Y, Irfan G, Casado-Arroyo R, Juliá J, La Meir M, Wellens F, Wauters K, Van Malderen S, Pappaert G and Brugada P. Prognostic value of programmed electrical stimulation in Brugada syndrome: 20 years experience. Circ Arrhythm Electrophysiol . 2015;8:777-84.
26. Denham NC, Pearman CM, Ding WY, Waktare J, Gupta D, Snowdon R, Hall M, Cooper R, Modi S, Todd D and Mahida S. Systematic re-evaluation of SCN5A variants associated with Brugada syndrome. J Cardiovasc Electrophysiol . 2019;30:118-127.
27. Walsh R and Wilde AAM. SCN5A variants in Brugada syndrome: True, true false, or false true. J Cardiovasc Electrophysiol . 2019;30:128-131.
28. Bébarová M, O’Hara T, Geelen JL, Jongbloed RJ, Timmermans C, Arens YH, Rodriguez LM, Rudy Y and Volders PG. Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation. Am J Physiol Heart Circ Physiol . 2008;295:H48-58.
29. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, Yamagishi M, Makita N, Sakurada H, Tanaka T, Shimizu A, Hagiwara N, Kishi R, Nakano Y, Takagi M, Makiyama T, Ohno S, Fukuda K, Watanabe H, Morita H, Hayashi K, Kusano K, Kamakura S, Yasuda S, Ogawa H, Miyamoto Y, Kapplinger JD, Ackerman MJ and Shimizu W. Genotype-Phenotype Correlation of.Circulation . 2017;135:2255-2270.
30. Lizotte E, Junttila MJ, Dube MP, Hong K, Benito B, DE Zutter M, Henkens S, Sarkozy A, Huikuri HV, Towbin J, Vatta M, Brugada P, Brugada J and Brugada R. Genetic modulation of brugada syndrome by a common polymorphism. J Cardiovasc Electrophysiol . 2009;20:1137-41.
31. Matsumura H, Nakano Y, Ochi H, Onohara Y, Sairaku A, Tokuyama T, Tomomori S, Motoda C, Amioka M, Hironobe N, Toshishige M, Takahashi S, Imai K, Sueda T, Chayama K and Kihara Y. H558R, a common SCN5A polymorphism, modifies the clinical phenotype of Brugada syndrome by modulating DNA methylation of SCN5A promoters. J Biomed Sci . 2017;24:91.